Erik Bjerregaard Pedersen

Erik Bjerregaard Pedersen

Auto-generated profile, based on publicly available information

Erik Bjerregaard Pedersen

Department of Physics Chemistry and Pharmacy University of Southern Denmark Campusvej 55 5230 Odense M Denmark

Research Focus & Metrics

Academic Career Length

50Years (1977-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1998 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KDKrzysztof Danel
Krzysztof Danel
EPErik B. Pedersen
Erik B. Pedersen
CNClaus Nielsen
Claus Nielsen

8 September 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AMAlexandro Membrino
Alexandro Membrino
SCSusanna Cogoi
Susanna Cogoi
EPErik B. Pedersen
Erik B. Pedersen
LXLuigi Xodo
Luigi Xodo
HRAS is a proto-oncogene involved in the tumorigenesis of urinary bladder cancer. In the HRAS promoter we identified two G-rich elements, hras-1 and hras-2, that fold, respectively, into an antiparallel and a parallel quadruplex (qhras-1, qhras-2). When we introduced in sequence hras-1 or hras-2 two point mutations that block quadruplex formation, transcription increased 5-fold, but when we stabilized the G-quadruplexes by guanidinium phthalocyanines, transcription decreased to 20% of control. By ChIP we found that sequence hras-1 is bound only by MAZ, while hras-2 is bound by MAZ and Sp1: two transcription factors recognizing guanine boxes. We also discovered by EMSA that recombinant MAZ-GST binds to both HRAS quadruplexes, while Sp1-GST only binds to qhras-1. The over-expression of MAZ and Sp1 synergistically activates HRAS transcription, while silencing each gene by RNAi results in a strong down-regulation of transcription. All these data indicate that the HRAS G-quadruplexes behave as transcription repressors. Finally, we designed decoy oligonucleotides mimicking the HRAS quadruplexes, bearing (R)-1-O-[4-(1-Pyrenylethynyl) phenylmethyl] glycerol and LNA modifications to increase their stability and nuclease resistance (G4-decoys). The G4-decoys repressed HRAS transcription and caused a strong antiproliferative effect, mediated by apoptosis, in T24 bladder cancer cells where HRAS is mutated.

1 January 1994 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AEAhmed A. El-Barbary
Ahmed A. El-Barbary
Ahmed I. KhodairAhmed I. Khodair
Ahmed I. Khodair
EPErik B. Pedersen
Erik B. Pedersen
CNClaus Nielsen
Claus Nielsen

6 March 2013 in Nucleic Acids Research
Verified
Journal Article
Open access
SCSusanna Cogoi
Susanna Cogoi
SZSonia Zorzet
Sonia Zorzet
VRValentina Rapozzi
Valentina Rapozzi
IGImrich Géci
Imrich Géci
EPErik B. Pedersen
Erik B. Pedersen
LXLuigi Xodo
Luigi Xodo
KRAS mutations are primary genetic lesions leading to pancreatic cancer. The promoter of human KRAS contains a nuclease-hypersensitive element (NHE) that can fold in G4-DNA structures binding to nuclear proteins, including MAZ (myc-associated zinc-finger). Here, we report that MAZ activates KRAS transcription. To knockdown oncogenic KRAS in pancreatic cancer cells, we designed oligonucleotides that mimic one of the G-quadruplexes formed by NHE (G4-decoys). To increase their nuclease resistance, two locked nucleic acid (LNA) modifications were introduced at the 3'-end, whereas to enhance the folding and stability, two polycyclic aromatic hydrocarbon units (TINA or AMANY) were inserted internally, to cap the quadruplex. The most active G4-decoy (2998), which had two para-TINAs, strongly suppressed KRAS expression in Panc-1 cells. It also repressed their metabolic activity (IC50 = 520 nM), and it inhibited cell growth and colony formation by activating apoptosis. We finally injected 2998 and control oligonucleotides 5153, 5154 (2 nmol/mouse) intratumorally in SCID mice bearing a Panc-1 xenograft. After three treatments, 2998 reduced tumor xenograft growth by 64% compared with control and increased the Kaplan-Meier median survival time by 70%. Together, our data show that MAZ-specific G4-decoys mimicking a KRAS quadruplex are promising for pancreatic cancer therapy.

1 December 1999 in Antiviral Chemistry and Chemotherapy
Verified
Journal Article
Open access
PDF file
OPOle S Pedersen
Ole S Pedersen
EPErik B Pedersen
Erik B Pedersen
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are promising drugs for the treatment of HIV when used in combination with other anti-HIV drugs such as nucleoside reverse transcriptase (RT) inhibitors and protease inhibitors. The first generation of NNRTIs have, however, suffered from the rapid development of resistance. This review discusses the properties of the FDA-approved NNRTI drugs and focuses on the recent efforts being made to produce second generation inhibitors that circumvent this resistance problem.